Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?

Zacks.com is assessing AbbVie (ABBV) stock's current investment recommendation (Buy, Hold, or Sell) following its notable year-to-date increase of nearly 23% as of September 16, 2025.

Analysis

AbbVie Inc. (ABBV) is under review following a significant year-to-date price appreciation of nearly 23% as of mid-September 2025. This strong performance has prompted a re-evaluation of the stock's investment case, questioning whether it remains a 'Buy', 'Hold', or 'Sell'. The prevailing sentiment surrounding this assessment is moderately positive but speculative, indicating that while underlying factors may be favorable, there is uncertainty about the sustainability of the rally. The analysis is framed around key investment themes including company fundamentals, analyst estimates, and market technicals, suggesting a comprehensive look at whether the stock's current valuation has outpaced its intrinsic value after the substantial run-up.

Key Decisions for Investors

• Investors currently holding ABBV should review their positions in light of the nearly 23% year-to-date gain to determine if the current valuation aligns with their risk tolerance and consider taking partial profits.
• Potential investors should exercise caution, as the significant price increase may have already priced in near-term positive catalysts, and should conduct thorough due diligence on the firm's fundamental outlook before initiating a new position.
• Monitor upcoming analyst reports and forward-looking guidance from the company, as the speculative tone suggests market participants are actively seeking confirmation that fundamentals can support the new, higher valuation.